Research programme: cancer therapeutics - Synlogic/RXi

Drug Profile

Research programme: cancer therapeutics - Synlogic/RXi

Alternative Names: RNAi-based cancer therapies - Synlogic/RXi Pharmaceuticals

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mirna Therapeutics; RXi Pharmaceuticals Corporation
  • Developer Mirna Therapeutics; RXi Pharmaceuticals
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 06 Jan 2016 Mirna Therapeutics sublicenses microRNA-related patents for oncology therapeutics from Rosetta Genomics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top